Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Inclusion Criteria: 1. Patients with glycogen storage disease type Ib (genetically diagnosed) aged ≥ 1 year and ≤ 50 years; 2. Patients meet the diagnostic criteria for Crohn's disease (CD) based on Expert consensus on the diagnosis and treatment of inflammatory bowel disease in Chinese children (2019) or Consensus opinion on the diagnosis and treatment of inflammatory bowel disease in China (2018), or patients meet the diagnostic criteria for recurrent respiratory tract infection based on Clinical diagnosis and treatment for recurrent respiratory tract infection in Chinese children (2022); 3. Subjects and their guardians/clients (\< 18 years old) or subjects (≥ 18 years old) signed the informed consent form. Exclusion Criteria: 1. Patients with chronic kidney disease (eGFR \< 60 ml/min/1.73 m\^2) or cirrhosis (Metavir F4); 2. Experiencing symptomatic or severe hypoglycemia within 1 month before the start of this trial; 3. Absolute neutrophil count continued ≥ 1.5 × 10\^9/L (≥ 3 tests, each interval ≥ 5 days); 4. Current active urinary tract infection (until urine routine twice negative); 5. Participating other clinical investigators in the past 1 month; 6. Pregnancy, breast-feeding and having a pregnancy plan; 7. Presence of contraindications to empagliflozin therapy (hypersensitivity to empagliflozin, current or history of gangrene, history of recurrent urinary or genital infections); 8. Patients who are not suitable for participating in the clinical investigator or with low compliance in the investigator 's opinion.